InterPAD - DETAILS

Apatinib, 811803-05-1, rivoceranib, Apatinib free base, N-(4-(1-Cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide, Apatinib (free base), YN968D1, N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide, 5S371K6132, N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide, 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, UNII-5S371K6132, apatinib (in China), RIVOCERANIB [INN], Rivoceranib (USAN/INN), RIVOCERANIB [USAN], RIVOCERANIB [WHO-DD], GTPL7648, SCHEMBL1814966, CHEMBL3186534, Apatinib free base; YN-968D1, DTXSID601024366, AMY21302, BCP02840, EX-A1794, HY-13342A, MFCD21648511, NSC772886, NSC799333, s5248, AKOS024464453, CCG-268625, DB14765, DS-7455, NSC-772886, NSC-799333, SB16590, N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, NCGC00249393-01, NCGC00249393-08, AC-27461, BA175030, DA-35324, CS-0003200, C76598, D11288, AB01274807-01, AB01274807_02, Q27262801, N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]nicotinamide, N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide

No.	Title	Href
1	A Synergistic Combination of Oleanolic Acid and Apatinib to Enhance Antitumor Effect on Liver Cancer Cells and Protect against Hepatic Injury. Recent Pat Anticancer Drug Discov. 2024;19(2):199-208. doi: 10.2174/1574892818666230417093208.	`Click`
2	Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells. Dis Markers. 2022 Jan 13;2022:3833489. doi: 10.1155/2022/3833489.	`Click`
3	Anti-proliferation effects of Apatinib in combination with Curcumin in breast cancer cells. Horm Mol Biol Clin Investig. 2022 Sep 5;44(1):27-32. doi: 10.1515/hmbci-2022-0036.	`Click`
4	Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway. Front Oncol. 2020 Sep 7;10:1732. doi: 10.3389/fonc.2020.01732.	`Click`

No.

Title

Href

A Synergistic Combination of Oleanolic Acid and Apatinib to Enhance Antitumor Effect on Liver Cancer Cells and Protect against Hepatic Injury. Recent Pat Anticancer Drug Discov. 2024;19(2):199-208. doi: 10.2174/1574892818666230417093208.

Click

Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells. Dis Markers. 2022 Jan 13;2022:3833489. doi: 10.1155/2022/3833489.

Click

Anti-proliferation effects of Apatinib in combination with Curcumin in breast cancer cells. Horm Mol Biol Clin Investig. 2022 Sep 5;44(1):27-32. doi: 10.1515/hmbci-2022-0036.

Click

Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway. Front Oncol. 2020 Sep 7;10:1732. doi: 10.3389/fonc.2020.01732.

Click

Name	Apatinib
PubChem CID	11315474
Molecular Weight	397.5g/mol
Synonyms	Apatinib, 811803-05-1, rivoceranib, Apatinib free base, N-(4-(1-Cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide, Apatinib (free base), YN968D1, N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide, 5S371K6132, N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide, 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, UNII-5S371K6132, apatinib (in China), RIVOCERANIB [INN], Rivoceranib (USAN/INN), RIVOCERANIB [USAN], RIVOCERANIB [WHO-DD], GTPL7648, SCHEMBL1814966, CHEMBL3186534, Apatinib free base; YN-968D1, DTXSID601024366, AMY21302, BCP02840, EX-A1794, HY-13342A, MFCD21648511, NSC772886, NSC799333, s5248, AKOS024464453, CCG-268625, DB14765, DS-7455, NSC-772886, NSC-799333, SB16590, N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, NCGC00249393-01, NCGC00249393-08, AC-27461, BA175030, DA-35324, CS-0003200, C76598, D11288, AB01274807-01, AB01274807_02, Q27262801, N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]nicotinamide, N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide
Drug Type	Small molecule
Formula	C₂₄H₂₃N₅O
SMILES	C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4
InChI	1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)
InChIKey	WPEWQEMJFLWMLV-UHFFFAOYSA-N
CAS Number	811803-05-1
ChEMBL ID	CHEMBL3186534
TTD ID	D0SZ6E
Drug Bank ID	DB14765
KEGG ID	D11289
Toxicity	Organism	Test Type	Route(Dose)
Structure			Download 2D MOL 3D MOL

Pair Name	Ginsenoside Rb1, Apatinib
Partner Name	Ginsenoside Rb1
Disease Info	[ICD-11: 2B6E]	Hypopharyngeal carcinoma		Investigative
Biological Phenomena	Induction-->Immunomodulatory
Gene Regulation	Up-regulation	Expression	CD4	hsa920
	Down-regulation	Expression	CD8A	hsa925
	Down-regulation	Expression	HK2	hsa3099
	Down-regulation	Expression	KDR	hsa3791
	Down-regulation	Expression	PECAM1	hsa5175
	Down-regulation	Expression	SLC2A4	hsa6517
	Down-regulation	Expression	SOX5	hsa6660
In Vitro Model	FaDu	Hypopharyngeal squamous cell carcinoma	Homo sapiens (Human)	CVCL_1218
In Vitro Model	Rca-B	Squamous cell carcinoma	Rattus norvegicus (Rat)	CVCL_5U48
Result	A combination of apatinib and G-Rb1 induced more tumor cell apoptosis and reduced cell proliferation than the individual drug treatment and promote antitumor immunity by enhancing immunomodulatory molecules. Thus, we believe that this study could serve as a valuable platform to assess the synergetic anticancer effects of the herbal as well as synthetic medicines.

Pair Name	Curcumin, Apatinib
Partner Name	Curcumin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	BIRC5	hsa332
	Up-regulation	Expression	DIABLO	hsa56616
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
Result	Apa-Cur combination therapy exerts more profound anti-proliferation effects on breast cancer cell than Apatinib or Curcumin monotherapy. However, further studies are required to identify other possible signaling pathways and mechanisms involved in the anticancer effects of Apatinib, Curcumin, and Apa-Cur.

Pair Name	Cordycepin, Apatinib
Partner Name	Cordycepin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Phosphorylation	PIK3CA	hsa5290
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
In Vitro Model	PC-9	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_B260
Result	Our findings demonstrated that the combination of cordycepin and apatinib has synergistically anticancer effect on NSCLC cells by down-regulating VEGF/PI3K/Akt signaling pathway. This result indicated that cordycepin and apatinib could be a promising drug combination against NSCLC.

Pair Name	Oleanolic Acid, Apatinib
Partner Name	Oleanolic Acid
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Oxidative Stress
In Vitro Model	H22	Hepatocellular carcinoma	Mus musculus (Mouse)	CVCL_H613
In Vivo Model	H22 tumor-burdened mice model was established in vivo.
Result	OA can treat apatinib induced liver injury in H22 Tumor-burdened mice by enhancing the suppresssive effect of apatinib on the growth of tumor.